Skip to main content

Immunotherapy improves survival in patients with advanced bladder cancer

An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles from Queen Mary's Barts Cancer Institute, and Barts Cancer Centre.

Published on:
Back to top